For heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis…. ANDA 90189, held by Fresenius Kabi USA. Bivalirudin.
As of Nov 16, 2026, ANDA 90189 (Bivalirudin), held by Fresenius Kabi USA, was first approved by FDA on Oct 28, 2016, with 1 approved supplement and 0 published complete response letters.
Bivalirudin for Injection is indicated for use as an anticoagulant for use in patients undergoing percutaneous coronary intervention (PCI) including patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Bivalirudin for Injection is a direct thrombin inhibitor indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI) including patients with heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis syndrome (HITTS).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 28, 2016 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Bivalirudin250MG/VIAL · injectable;intravenous | Bivalirudin | Rx |
| Apr 14, 2021 | Supplement 2Labeling · Standard review | Approved | None posted |
| Oct 28, 2016 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters